Jul 5, 2023 · In the FATA-GIM3 clinical trial: Aromasin 25 mg per day resulted in a 5-year disease-free survival rate of 88%, but ranged between 85
4%, with a range between 87
Whereas tamoxifen interferes with the ability of breast cancer cells to
Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level
A large, randomized trial is presently also underway comparing
The cause of the increased incidence of cardiac events of grade 3, 4, or 5 in the letrozole group, as compared with the tamoxifen group (2
Previously they had shown that use of exemestane after 2–3 years of tamoxifen therapy significantly improves disease-free survival in
And they may be an option for people who no longer benefit from tamoxifen treatment or whose treatment is
They were assigned to initial treatment with either exemestane or tamoxifen; after 2
The number of patients with death, contralateral breast cancer, or recurrence was lower in the exemestane group (183 versus 266 in the tamoxifen group; 7
There was a significant difference between the treatment groups regarding time to endometrial thickness > 10 mm, in favour of exemestane (p < 0
75 years, differences in the AE incidence between exemestane and tamoxifen included an increase in certain musculoskeletal events for exemestane
Aromasin contains the active drug exemestane
Side effects, mostly bone pain that eventually moved to my feet, were horrible as my job requires a lot of walking
Dirix et al
Differences in mean changes (exemestane–tamoxifen) of these measures (where negative values indicate greater change in the tamoxifen group than in the exemestane group) if the difference between the groups is >1% or if the difference between treatment groups resulted in a P value of <0
Occurrence of carpal tunnel syndrome is higher in patients with breast cancer given exemestane than in those treated with tamoxifen, and surgical release might be necessary in most cases
It is also used in women who have been treated with Tamoxifen previously for 2-3 years or whose Breast Cancer worsened due to Tamoxifen
A mechanism explaining the additive effects of the steroidal AI exemestane in combination with tamoxifen has not been established